Researchers design gene therapy that can effectively target glioblastoma
In a first-in-human phase 1 trial in 41 patients with recurrent glioblastoma, an oncolytic virus treatment designed by Brigham researchers extended survival, especially among those with pre-existing viral antibodies
Therapy turns ‘immune desert’ into inflammatory cancer-fighting zone
Study demonstrated the safety and preliminary efficacy of a novel gene therapy for glioblastoma
Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months. Immunotherapies, ...
















